Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 118 entries
Sorted by: Best Match Show Resources per page
Comparison of Medication Alerts from Two Commercial Applications in the USA.

Drug safety

Shah SN, Seger DL, Fiskio JM, Horn JR, Bates DW.
PMID: 33616888
Drug Saf. 2021 Jun;44(6):661-668. doi: 10.1007/s40264-021-01048-0. Epub 2021 Feb 22.

INTRODUCTION: Medication organizations across the USA have adopted electronic health records, and one of the most anticipated benefits of these was improved medication safety, but alert fatigue has been a major issue.OBJECTIVE: We compared the appropriateness of medication-related clinical...

Cite
Shah SN, Seger DL, Fiskio JM, et al. Comparison of Medication Alerts from Two Commercial Applications in the USA. Drug Saf. 2021;44(6):661-668doi: 10.1007/s40264-021-01048-0.
Shah, S. N., Seger, D. L., Fiskio, J. M., Horn, J. R., & Bates, D. W. (2021). Comparison of Medication Alerts from Two Commercial Applications in the USA. Drug safety, 44(6), 661-668. https://doi.org/10.1007/s40264-021-01048-0
Shah, Sonam N, et al. "Comparison of Medication Alerts from Two Commercial Applications in the USA." Drug safety vol. 44,6 (2021): 661-668. doi: https://doi.org/10.1007/s40264-021-01048-0
Shah SN, Seger DL, Fiskio JM, Horn JR, Bates DW. Comparison of Medication Alerts from Two Commercial Applications in the USA. Drug Saf. 2021 Jun;44(6):661-668. doi: 10.1007/s40264-021-01048-0. Epub 2021 Feb 22. PMID: 33616888; PMCID: PMC8184526.
Copy Download .nbib Format: NLM
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.

British journal of haematology

Abdel Rahman ZH, Parrondo RD, Heckman MG, Wieczorek M, Miller KC, Alkhateeb H, Sproat LZ, Murthy H, Hogan WJ, Kharfan-Dabaja MA, Peterson JF, Baughn LB, Hoppman N, Litzow MR, Ketterling RP, Greipp PT, Foran JM.
PMID: 34697797
Br J Haematol. 2021 Oct 25; doi: 10.1111/bjh.17906. Epub 2021 Oct 25.

We report a comparative analysis of patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) vs de novo ALL. We identified 331 patients with B-ALL; 69 (21%) were classified as tr-ALL. The most common prior malignancies were breast (23·2%) and plasma...

Cite
Abdel Rahman ZH, Parrondo RD, Heckman MG, et al. Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. Br J Haematol. 2021;doi: 10.1111/bjh.17906.
Abdel Rahman, Z. H., Parrondo, R. D., Heckman, M. G., Wieczorek, M., Miller, K. C., Alkhateeb, H., Sproat, L. Z., Murthy, H., Hogan, W. J., Kharfan-Dabaja, M. A., Peterson, J. F., Baughn, L. B., Hoppman, N., Litzow, M. R., Ketterling, R. P., Greipp, P. T., & Foran, J. M. (2021). Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. British journal of haematology, . https://doi.org/10.1111/bjh.17906
Abdel Rahman, Zaid H, et al. "Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17906
Abdel Rahman ZH, Parrondo RD, Heckman MG, Wieczorek M, Miller KC, Alkhateeb H, Sproat LZ, Murthy H, Hogan WJ, Kharfan-Dabaja MA, Peterson JF, Baughn LB, Hoppman N, Litzow MR, Ketterling RP, Greipp PT, Foran JM. Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. Br J Haematol. 2021 Oct 25; doi: 10.1111/bjh.17906. Epub 2021 Oct 25. PMID: 34697797.
Copy Download .nbib Format: NLM
A survey of early-career researchers in Australia.

eLife

Christian K, Johnstone C, Larkins JA, Wright W, Doran MR.
PMID: 33423739
Elife. 2021 Jan 11;10. doi: 10.7554/eLife.60613.

Early-career researchers (ECRs) make up a large portion of the academic workforce and their experiences often reflect the wider culture of the research system. Here we surveyed 658 ECRs working in Australia to better understand the needs and challenges...

Cite
Christian K, Johnstone C, Larkins JA, et al. A survey of early-career researchers in Australia. Elife. 2021;10doi: 10.7554/eLife.60613.
Christian, K., Johnstone, C., Larkins, J. A., Wright, W., & Doran, M. R. (2021). A survey of early-career researchers in Australia. eLife, 10. https://doi.org/10.7554/eLife.60613
Christian, Katherine, et al. "A survey of early-career researchers in Australia." eLife vol. 10 (2021). doi: https://doi.org/10.7554/eLife.60613
Christian K, Johnstone C, Larkins JA, Wright W, Doran MR. A survey of early-career researchers in Australia. Elife. 2021 Jan 11;10. doi: 10.7554/eLife.60613. PMID: 33423739; PMCID: PMC7800379.
Copy Download .nbib Format: NLM
Correction: SIGIRR Negatively Regulates IL-36-Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin.

Journal of immunology (Baltimore, Md. : 1950)

Giannoudaki E, Stefanska AM, Lawler H, Leon G, Hernandez Santana YE, Hassan N, Russell SE, Horan R, Sweeney C, Preston RS, Mantovani A, Garlanda C, Fallon PG, Walsh PT.
PMID: 34697229
J Immunol. 2021 Dec 01;207(11):2895. doi: 10.4049/jimmunol.2100907. Epub 2021 Oct 25.

No abstract available.

Cite
Giannoudaki E, Stefanska AM, Lawler H, et al. Correction: SIGIRR Negatively Regulates IL-36-Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin. J Immunol. 2021;207(11):2895doi: 10.4049/jimmunol.2100907.
Giannoudaki, E., Stefanska, A. M., Lawler, H., Leon, G., Hernandez Santana, Y. E., Hassan, N., Russell, S. E., Horan, R., Sweeney, C., Preston, R. S., Mantovani, A., Garlanda, C., Fallon, P. G., & Walsh, P. T. (2021). Correction: SIGIRR Negatively Regulates IL-36-Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin. Journal of immunology (Baltimore, Md. : 1950), 207(11), 2895. https://doi.org/10.4049/jimmunol.2100907
Giannoudaki, Eirini, et al. "Correction: SIGIRR Negatively Regulates IL-36-Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin." Journal of immunology (Baltimore, Md. : 1950) vol. 207,11 (2021): 2895. doi: https://doi.org/10.4049/jimmunol.2100907
Giannoudaki E, Stefanska AM, Lawler H, Leon G, Hernandez Santana YE, Hassan N, Russell SE, Horan R, Sweeney C, Preston RS, Mantovani A, Garlanda C, Fallon PG, Walsh PT. Correction: SIGIRR Negatively Regulates IL-36-Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin. J Immunol. 2021 Dec 01;207(11):2895. doi: 10.4049/jimmunol.2100907. Epub 2021 Oct 25. PMID: 34697229.
Copy Download .nbib Format: NLM
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

Leukemia

Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U.
PMID: 34172893
Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25.

We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 were...

Cite
Steensma DP, Wermke M, Klimek VM, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35(12):3542-3550doi: 10.1038/s41375-021-01328-9.
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Ades, L., Al-Kali, A., Alonso-Dominguez, J. M., Alfonso-Piérola, A., Coombs, C. C., Deeg, H. J., Flinn, I., Foran, J. M., Garcia-Manero, G., Maris, M. B., McMasters, M., Micol, J. B., De Oteyza, J. P., Thol, F., Wang, E. S., Watts, J. M., Taylor, J., Stone, R., Gourineni, V., Marino, A. J., Yao, H., Destenaves, B., Yuan, X., Yu, K., Dar, S., Ohanjanian, L., Kuida, K., Xiao, J., Scholz, C., Gualberto, A., & Platzbecker, U. (2021). Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 35(12), 3542-3550. https://doi.org/10.1038/s41375-021-01328-9
Steensma, David P, et al. "Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms." Leukemia vol. 35,12 (2021): 3542-3550. doi: https://doi.org/10.1038/s41375-021-01328-9
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. PMID: 34172893; PMCID: PMC8632688.
Copy Download .nbib Format: NLM
A Smartwatch Paired With A Mobile Application Provides Postoperative Self-Directed Rehabilitation Without Compromising Total Knee Arthroplasty Outcomes: A Randomized Controlled Trial.

The Journal of arthroplasty

Tripuraneni KR, Foran JRH, Munson NR, Racca NE, Carothers JT.
PMID: 34462184
J Arthroplasty. 2021 Dec;36(12):3888-3893. doi: 10.1016/j.arth.2021.08.007. Epub 2021 Aug 09.

BACKGROUND: Self-directed rehabilitation (SDR) after total knee arthroplasty (TKA) has not been traditionally recommended. The purpose of this study was to determine if there was an impact on postoperative outcomes with the use of an SDR program after primary...

Cite
Tripuraneni KR, Foran JRH, Munson NR, et al. A Smartwatch Paired With A Mobile Application Provides Postoperative Self-Directed Rehabilitation Without Compromising Total Knee Arthroplasty Outcomes: A Randomized Controlled Trial. J Arthroplasty. 2021;36(12):3888-3893doi: 10.1016/j.arth.2021.08.007.
Tripuraneni, K. R., Foran, J. R. H., Munson, N. R., Racca, N. E., & Carothers, J. T. (2021). A Smartwatch Paired With A Mobile Application Provides Postoperative Self-Directed Rehabilitation Without Compromising Total Knee Arthroplasty Outcomes: A Randomized Controlled Trial. The Journal of arthroplasty, 36(12), 3888-3893. https://doi.org/10.1016/j.arth.2021.08.007
Tripuraneni, Krishna R, et al. "A Smartwatch Paired With A Mobile Application Provides Postoperative Self-Directed Rehabilitation Without Compromising Total Knee Arthroplasty Outcomes: A Randomized Controlled Trial." The Journal of arthroplasty vol. 36,12 (2021): 3888-3893. doi: https://doi.org/10.1016/j.arth.2021.08.007
Tripuraneni KR, Foran JRH, Munson NR, Racca NE, Carothers JT. A Smartwatch Paired With A Mobile Application Provides Postoperative Self-Directed Rehabilitation Without Compromising Total Knee Arthroplasty Outcomes: A Randomized Controlled Trial. J Arthroplasty. 2021 Dec;36(12):3888-3893. doi: 10.1016/j.arth.2021.08.007. Epub 2021 Aug 09. PMID: 34462184.
Copy Download .nbib Format: NLM
Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes.

Blood cancer journal

Abdel-Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, Alkhateeb HB, Sproat LZ, Khera N, Murthy HS, Ayala E, Hogan WJ, Roy V, Peterson JF, Kharfan-Dabaja MA, Ketterling RP, Litzow MR, Baughn LB, Patnaik M, Greipp PT, Foran JM.
PMID: 34548472
Blood Cancer J. 2021 Sep 21;11(9):156. doi: 10.1038/s41408-021-00538-9.

No abstract available.

Cite
Abdel-Rahman ZH, Heckman MG, Anagnostou T, et al. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. Blood Cancer J. 2021;11(9):156doi: 10.1038/s41408-021-00538-9.
Abdel-Rahman, Z. H., Heckman, M. G., Anagnostou, T., White, L. J., Kloft-Nelson, S. M., Knudson, R. A., Alkhateeb, H. B., Sproat, L. Z., Khera, N., Murthy, H. S., Ayala, E., Hogan, W. J., Roy, V., Peterson, J. F., Kharfan-Dabaja, M. A., Ketterling, R. P., Litzow, M. R., Baughn, L. B., Patnaik, M., Greipp, P. T., & Foran, J. M. (2021). Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. Blood cancer journal, 11(9), 156. https://doi.org/10.1038/s41408-021-00538-9
Abdel-Rahman, Zaid H, et al. "Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes." Blood cancer journal vol. 11,9 (2021): 156. doi: https://doi.org/10.1038/s41408-021-00538-9
Abdel-Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, Alkhateeb HB, Sproat LZ, Khera N, Murthy HS, Ayala E, Hogan WJ, Roy V, Peterson JF, Kharfan-Dabaja MA, Ketterling RP, Litzow MR, Baughn LB, Patnaik M, Greipp PT, Foran JM. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. Blood Cancer J. 2021 Sep 21;11(9):156. doi: 10.1038/s41408-021-00538-9. PMID: 34548472; PMCID: PMC8455651.
Copy Download .nbib Format: NLM
Ecosystem response persists after a prolonged marine heatwave.

Scientific reports

Suryan RM, Arimitsu ML, Coletti HA, Hopcroft RR, Lindeberg MR, Barbeaux SJ, Batten SD, Burt WJ, Bishop MA, Bodkin JL, Brenner R, Campbell RW, Cushing DA, Danielson SL, Dorn MW, Drummond B, Esler D, Gelatt T, Hanselman DH, Hatch SA, Haught S, Holderied K, Iken K, Irons DB, Kettle AB, Kimmel DG, Konar B, Kuletz KJ, Laurel BJ, Maniscalco JM, Matkin C, McKinstry CAE, Monson DH, Moran JR, Olsen D, Palsson WA, Pegau WS, Piatt JF, Rogers LA, Rojek NA, Schaefer A, Spies IB, Straley JM, Strom SL, Sweeney KL, Szymkowiak M, Weitzman BP, Yasumiishi EM, Zador SG.
PMID: 33737519
Sci Rep. 2021 Mar 18;11(1):6235. doi: 10.1038/s41598-021-83818-5.

Some of the longest and most comprehensive marine ecosystem monitoring programs were established in the Gulf of Alaska following the environmental disaster of the Exxon Valdez oil spill over 30 years ago. These monitoring programs have been successful in...

Cite
Suryan RM, Arimitsu ML, Coletti HA, et al. Ecosystem response persists after a prolonged marine heatwave. Sci Rep. 2021;11(1):6235doi: 10.1038/s41598-021-83818-5.
Suryan, R. M., Arimitsu, M. L., Coletti, H. A., Hopcroft, R. R., Lindeberg, M. R., Barbeaux, S. J., Batten, S. D., Burt, W. J., Bishop, M. A., Bodkin, J. L., Brenner, R., Campbell, R. W., Cushing, D. A., Danielson, S. L., Dorn, M. W., Drummond, B., Esler, D., Gelatt, T., Hanselman, D. H., Hatch, S. A., Haught, S., Holderied, K., Iken, K., Irons, D. B., Kettle, A. B., Kimmel, D. G., Konar, B., Kuletz, K. J., Laurel, B. J., Maniscalco, J. M., Matkin, C., McKinstry, C. A. E., Monson, D. H., Moran, J. R., Olsen, D., Palsson, W. A., Pegau, W. S., Piatt, J. F., Rogers, L. A., Rojek, N. A., Schaefer, A., Spies, I. B., Straley, J. M., Strom, S. L., Sweeney, K. L., Szymkowiak, M., Weitzman, B. P., Yasumiishi, E. M., & Zador, S. G. (2021). Ecosystem response persists after a prolonged marine heatwave. Scientific reports, 11(1), 6235. https://doi.org/10.1038/s41598-021-83818-5
Suryan, Robert M, et al. "Ecosystem response persists after a prolonged marine heatwave." Scientific reports vol. 11,1 (2021): 6235. doi: https://doi.org/10.1038/s41598-021-83818-5
Suryan RM, Arimitsu ML, Coletti HA, Hopcroft RR, Lindeberg MR, Barbeaux SJ, Batten SD, Burt WJ, Bishop MA, Bodkin JL, Brenner R, Campbell RW, Cushing DA, Danielson SL, Dorn MW, Drummond B, Esler D, Gelatt T, Hanselman DH, Hatch SA, Haught S, Holderied K, Iken K, Irons DB, Kettle AB, Kimmel DG, Konar B, Kuletz KJ, Laurel BJ, Maniscalco JM, Matkin C, McKinstry CAE, Monson DH, Moran JR, Olsen D, Palsson WA, Pegau WS, Piatt JF, Rogers LA, Rojek NA, Schaefer A, Spies IB, Straley JM, Strom SL, Sweeney KL, Szymkowiak M, Weitzman BP, Yasumiishi EM, Zador SG. Ecosystem response persists after a prolonged marine heatwave. Sci Rep. 2021 Mar 18;11(1):6235. doi: 10.1038/s41598-021-83818-5. PMID: 33737519; PMCID: PMC7973763.
Copy Download .nbib Format: NLM
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.

American journal of hematology

Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, Foran JM, Granroth GL, Olteanu H, Kadia T, Tefferi A, Pemmaraju N.
PMID: 34807470
Am J Hematol. 2021 Nov 22; doi: 10.1002/ajh.26417. Epub 2021 Nov 22.

No abstract available.

Cite
Gangat N, Konopleva M, Patnaik MM, et al. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2021;doi: 10.1002/ajh.26417.
Gangat, N., Konopleva, M., Patnaik, M. M., Jabbour, E., DiNardo, C., Al-Kali, A., Foran, J. M., Granroth, G. L., Olteanu, H., Kadia, T., Tefferi, A., & Pemmaraju, N. (2021). Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American journal of hematology, . https://doi.org/10.1002/ajh.26417
Gangat, Naseema, et al. "Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm." American journal of hematology vol. (2021). doi: https://doi.org/10.1002/ajh.26417
Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, Foran JM, Granroth GL, Olteanu H, Kadia T, Tefferi A, Pemmaraju N. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2021 Nov 22; doi: 10.1002/ajh.26417. Epub 2021 Nov 22. PMID: 34807470.
Copy Download .nbib Format: NLM
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

Leukemia

Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U.
PMID: 34172893
Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25.

We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 were...

Cite
Steensma DP, Wermke M, Klimek VM, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35(12):3542-3550doi: 10.1038/s41375-021-01328-9.
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Ades, L., Al-Kali, A., Alonso-Dominguez, J. M., Alfonso-Piérola, A., Coombs, C. C., Deeg, H. J., Flinn, I., Foran, J. M., Garcia-Manero, G., Maris, M. B., McMasters, M., Micol, J. B., De Oteyza, J. P., Thol, F., Wang, E. S., Watts, J. M., Taylor, J., Stone, R., Gourineni, V., Marino, A. J., Yao, H., Destenaves, B., Yuan, X., Yu, K., Dar, S., Ohanjanian, L., Kuida, K., Xiao, J., Scholz, C., Gualberto, A., & Platzbecker, U. (2021). Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 35(12), 3542-3550. https://doi.org/10.1038/s41375-021-01328-9
Steensma, David P, et al. "Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms." Leukemia vol. 35,12 (2021): 3542-3550. doi: https://doi.org/10.1038/s41375-021-01328-9
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. PMID: 34172893.
Copy Download .nbib Format: NLM
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F.
PMID: 34156898
J Clin Oncol. 2021 Oct 10;39(29):3261-3272. doi: 10.1200/JCO.20.01739. Epub 2021 Jun 22.

PURPOSE: Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection during induction chemotherapy.PATIENTS AND METHODS: One hundred...

Cite
Desai PM, Brown J, Gill S, et al. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021;39(29):3261-3272doi: 10.1200/JCO.20.01739.
Desai, P. M., Brown, J., Gill, S., Solh, M. M., Akard, L. P., Hsu, J. W., Ustun, C., Andreadis, C., Frankfurt, O., Foran, J. M., Lister, J., Schiller, G. J., Wieduwilt, M. J., Pagel, J. M., Stiff, P. J., Liu, D., Khan, I., Stock, W., Kambhampati, S., Tallman, M. S., Morris, L., Edwards, J., Pusic, I., Kantarjian, H. M., Mamelok, R., Wong, A., Van Syoc, R., Kellerman, L., Panuganti, S., Mandalam, R., Abboud, C. N., & Ravandi, F. (2021). Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(29), 3261-3272. https://doi.org/10.1200/JCO.20.01739
Desai, Pinkal M, et al. "Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,29 (2021): 3261-3272. doi: https://doi.org/10.1200/JCO.20.01739
Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 Oct 10;39(29):3261-3272. doi: 10.1200/JCO.20.01739. Epub 2021 Jun 22. PMID: 34156898; PMCID: PMC8500663.
Copy Download .nbib Format: NLM
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

Leukemia

Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U.
PMID: 34172893
Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25.

We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 were...

Cite
Steensma DP, Wermke M, Klimek VM, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35(12):3542-3550doi: 10.1038/s41375-021-01328-9.
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Ades, L., Al-Kali, A., Alonso-Dominguez, J. M., Alfonso-Piérola, A., Coombs, C. C., Deeg, H. J., Flinn, I., Foran, J. M., Garcia-Manero, G., Maris, M. B., McMasters, M., Micol, J. B., De Oteyza, J. P., Thol, F., Wang, E. S., Watts, J. M., Taylor, J., Stone, R., Gourineni, V., Marino, A. J., Yao, H., Destenaves, B., Yuan, X., Yu, K., Dar, S., Ohanjanian, L., Kuida, K., Xiao, J., Scholz, C., Gualberto, A., & Platzbecker, U. (2021). Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 35(12), 3542-3550. https://doi.org/10.1038/s41375-021-01328-9
Steensma, David P, et al. "Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms." Leukemia vol. 35,12 (2021): 3542-3550. doi: https://doi.org/10.1038/s41375-021-01328-9
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. PMID: 34172893; PMCID: PMC8632688.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 118 entries